ebeam4therapy
Financiado
Very High Energy Electrons Beam for Radiotherapy
Despite advanced treatment planning and delivery, conventional oncologic radiotherapy (RT) is limited by acute toxicity and long-term side effects caused by radiation delivery to healthy tissues, which often restricts the ability...
Despite advanced treatment planning and delivery, conventional oncologic radiotherapy (RT) is limited by acute toxicity and long-term side effects caused by radiation delivery to healthy tissues, which often restricts the ability to deliver a sufficient dose of radiation to the tumours. The problem is exacerbated when treating cancers that are either deep down inside the human body, or in delicate areas where toxicity to nearby organs could cause serious side effects, especially when treating obese patients, whose numbers are increasing globally. Thus, an accessible and cost-effective alternative to current RT modalities is urgently needed. In ERC-PoC project Vherapy we made a breakthrough in demonstrating the viability of delivering high-quality particle beams with compact laser plasma accelerators for very high energy electron radiotherapy (VHEE-RT). We demonstrated that such a VHEE beam can be produced with a single laser beam using a new injection scheme, making the acceleration machinery small, simple and cost effective, thereby giving this device of the future substantial competitive advantage. The objectives of the eBeam4Therapy project are to optimize VHEE beam performances for radiotherapy applications further, to characterise the 3D dose deposition, to improve and scale-down each component of the machine, and finally to build a machine prototype that demonstrates the technical feasibility in an economically competitive setting. The commercial feasibility is validated with real market players and the project expands the existing network of collaborators and sources additional investment to accomplish the next steps in technological & commercial development to speed up market entry. eBeam4Therapy aims to revolutionise cancer therapy by providing better clinical outcomes and radically improving the quality of life of cancer patients at a lower financial burden to payers and economies, thus addressing a real and immediate global societal challenge.
ver más
Duración del proyecto: 40 meses
Fecha Inicio: 2022-03-17
Fecha Fin: 2025-07-31
Fecha Fin: 2025-07-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-03-17
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2021-TRANSITIONOPEN-01:
EIC Transition Open 2021
Cerrada
hace 3 años
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
WEIZMANN INSTITUTE OF SCIENCE
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
415.63K€ |
Participante